Comparison of dexmedetomidine and remimazolam in conscious sedation for percutaneous thermal ablation of liver tumor: a randomized controlled study
Not Applicable
Completed
- Conditions
- Neoplasms
- Registration Number
- KCT0008873
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
conscious sedation for percutaneous thermal ablation of liver tumor
ASA class I - III
Exclusion Criteria
1) contraindicated for benzodiazepine-class medication administration (e.g., patients with a known allergy to the drug or a history of hypersensitivity reactions).
2) the patient refuses
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient satisfaction was expressed by the PSSI
- Secondary Outcome Measures
Name Time Method Satisfaction of interventionist (1 : Very dissatisfied ~ 5 : Very satisfied);Satisfaction of anesthesiologist (by CSSI questionnaire);Hemodynamic stability (incidence of hypotension(MBP<65mmHg), hypertension(MBP>100mmHg) or bradycardia (<45beats/min), use of drugs);Adverse effect related procedure (Failure of complete ablation - CT findings, hemorrhage(;Sedation level (MOAA/S scale);Time to Respond After Procedure Completion;Dosage of drugs (dexmedetomidine, remimazolam, remifentanil);conscious level in recovery room (RASS);pain score (NRS 0-10);Nause and vomiting (0:none 1:mild 2:moderate 3:severe);Level of memory recall during the procedure